ANDA 77919, held by Emed Medcl. Terbinafine Hydrochloride.
As of Nov 22, 2026, ANDA 77919 (Terbinafine Hydrochloride), held by Emed Medcl, was first approved by FDA on Jul 2, 2007, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbinafine HydrochlorideEQ 250MG BASE · tablet;oral | Terbinafine Hydrochloride | Rx |
| Oct 28, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 28, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 29, 2012 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 29, 2012 | Supplement 3Labeling | Approved | None posted |
| Nov 10, 2011 | Supplement 2Labeling | Approved | None posted |
| Jul 2, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters